HD2 | DCN1 inhibitor
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $75.00 | ||
| 25 mg | $250.00 |
HD2 (2543578-57-8) is a potent (IC50 = 2.96 nM) inhibitor of DCN1, an important co-E3 ligase of neddylation. Displays favorable pharmacokinetics and low toxicity (including no hepatotoxicity). Selective against other DCN family members as well as ACE. HD2 reduced the migration and proliferation of Ang II-treated cardiac fibroblasts. Active in an isoproterenol-induced pathological cardiac remodeling and fibrosis mouse model. HD2 is a promising new therapeutic option for treatment of cardiac remodeling and fibrosis.
References/CItations:
- He et al. (2024), Discovery of 1,2,4-Triazole-3-thione Derivatives AS Potent and Selective DCN1 Inhibitors for Pathological Cardiac Fibrosis and Remodeling; J. Med. Chem. 67 18699
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
HD2 (2543578-57-8) is a potent (IC50 = 2.96 nM) inhibitor of DCN1, an important co-E3 ligase of neddylation. Displays favorable pharmacokinetics and low toxicity (including no hepatotoxicity). Selective against other DCN family members as well as ACE. HD2 reduced the migration and proliferation of Ang II-treated cardiac fibroblasts. Active in an isoproterenol-induced pathological cardiac remodeling and fibrosis mouse model. HD2 is a promising new therapeutic option for treatment of cardiac remodeling and fibrosis.
References/CItations:
- He et al. (2024), Discovery of 1,2,4-Triazole-3-thione Derivatives AS Potent and Selective DCN1 Inhibitors for Pathological Cardiac Fibrosis and Remodeling; J. Med. Chem. 67 18699
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass